Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

982
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
982
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Change of Cervical Cancer Stage at Diagnosis After the COVID-19 Pandemic.

Cureus·2026
Same author

Outpatient Delivery of Step-Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma.

European journal of haematology·2026
Same author

Tuberculosis reactivation in hematopoietic stem cell transplant recipients: a preemptive strategy in an endemic country.

Journal of clinical tuberculosis and other mycobacterial diseases·2025
Same author

Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study.

Scientific reports·2025
Same author

Development of Polyvinyl Alcohol Hydrogels for Controlled Glucose Release in Biomedical Applications.

Gels (Basel, Switzerland)·2024
Same author

Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia.

Cancer causes & control : CCC·2024

Related Experiment Video

Updated: Jul 16, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.7K

Essential thrombocythaemia.

Gilberto Barranco-Lampón1,2, Raúl Martínez-Castro3, Luara Arana-Luna4

  • 1Servicio de Hematología, Hospital General de México, Ciudad de México, México.

Gaceta Medica De Mexico
|September 21, 2023
PubMed
Summary

Essential thrombocythemia (ET) is a chronic blood cancer affecting platelet production. Current treatments focus on managing bleeding and clotting risks for patients diagnosed using 2016 WHO criteria.

Keywords:
Essential thrombocythemiaMyeloproliferative neoplasmsNeoplasias mieloproliferativasThrombocytosisTrombocitemia esencialTrombocitosis

More Related Videos

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

548
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.0K

Related Experiment Videos

Last Updated: Jul 16, 2025

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.7K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

548
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.0K

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm.
  • It involves the megakaryopoietic lineage, leading to sustained thrombocytosis and increased megakaryocytes.
  • ET presents with thrombocytosis, increased thrombotic/hemorrhagic risk, and constitutional symptoms.

Purpose of the Study:

  • To summarize the characteristics of Essential Thrombocythemia.
  • To outline diagnostic criteria and current therapeutic goals for ET.

Main Methods:

  • Diagnosis relies on the 2016 World Health Organization (WHO) criteria.
  • Review of existing literature on Essential Thrombocythemia.

Main Results:

  • ET is characterized by sustained high platelet counts and megakaryocyte proliferation.
  • Patients face risks of thrombosis, hemorrhage, and potential progression to myelofibrosis or acute leukemia.
  • Constitutional symptoms are common in ET patients.

Conclusions:

  • Essential thrombocythemia requires careful management due to associated risks.
  • Current treatment strategies primarily aim to mitigate thrombotic and hemorrhagic complications.